Biotechnology for a Conservative Japanese Drug Industry
Japanese drug companies remain high conservative, reluctant to expand beyond a national or regional focus to create worldwide pharmaceutical businesses. More are turning to biotech collaborations to provide new products, particularly favoring combinatorial chemistry deals which are relatively inexpensive and have short-term payoffs.
You may also be interested in...ï»¿
The US FDA released five device-related close-out letters in March.
Governments around the world should designate all medicines as ‘priority essential products’, the IGBA has urged, as a surge in demand coinciding with a reduction in the number of flights and rising freight costs are making it more difficult for suppliers to meet global requirements amid the coronavirus pandemic.
In a letter to the medtech industry, the FDA’s William Maisel says the US agency will hold remote meetings with device makers and other stakeholders through the end of May. The FDA also extended due dates for marketing applications by 90 days.